为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌的免疫治疗
英文原题：Immunotherapy for hepatocellular carcinoma.
查看英文原题
Immunotherapy for hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是起源于肝脏的原发性恶性肿瘤，发病常见，危害人类健康，在全球癌症中发病率位居第六。由于疾病晚期才出现症状，肝细胞癌较难确诊；许多患者确诊时病情已进展到无法接受肝移植、手术切除乃至局部治疗的阶段。肝细胞癌的进展受免疫系统调控，而免疫治疗可调动机体免疫防御机制靶向肝癌细胞，因此为肝细胞癌治疗带来了新的希望。目前，肝癌免疫治疗主要包括免疫检查点抑制剂、肝癌疫苗和细胞治疗。本文综述了免疫治疗肝细胞癌的研究进展。
展开英文摘要原文
Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is a threat to the health of all humans as a prevalent malignancy and is the sixth most common cancer worldwide. It is difficult to diagnose because symptoms do not show up until late in the disease, and patients often progress to the point where transplantation, resection, or even local treatment cannot be performed.
The progression of HCC is regulated by the immune system, and immunotherapy enables the body's immune system's defenses to target liver cancer cells; therefore, immunotherapy has brought a new hope for the treatment of HCC. Currently, the main types of immunotherapies for liver cancer are: immune checkpoint inhibitors, liver cancer vaccines and cellular therapies. In this review, the progress of immunotherapy for the treatment of HCC is summarized.
论文信息
- 作者
- Zhou M、Liu B、Shen J
- 第一作者单位
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.China
- 通讯作者单位
- The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. shenjie2008nju@163.com.China
- 文献类型
- 综述
- 期刊
- Clinical and experimental medicine2023 Jul
- 原文标识
- PubMed 36001163 · DOI 10.1007/s10238-022-00874-5